Proteases, Protease-Activated Receptors, and Atherosclerosis.
作者信息
Ruf Wolfram
机构信息
From the Center for Thrombosis and Hemostasis, Johannes Gutenberg University Medical Center, Mainz, Germany; and Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA.
出版信息
Arterioscler Thromb Vasc Biol. 2018 Jun;38(6):1252-1254. doi: 10.1161/ATVBAHA.118.311139.
Abstract
摘要
相似文献
1
Proteases, Protease-Activated Receptors, and Atherosclerosis.
Arterioscler Thromb Vasc Biol. 2018 Jun;38(6):1252-1254. doi: 10.1161/ATVBAHA.118.311139.
2
The role of protease activation of inflammation in allergic respiratory diseases.
J Allergy Clin Immunol. 2004 Nov;114(5):997-1008; quiz 1009. doi: 10.1016/j.jaci.2004.07.060.
3
A novel therapeutic target in various lung diseases: airway proteases and protease-activated receptors.
Pharmacol Ther. 2007 Jul;115(1):70-83. doi: 10.1016/j.pharmthera.2007.04.002. Epub 2007 Apr 19.
4
Extracellular mediators in atherosclerosis and thrombosis: lessons from thrombin receptor knockout mice.
Arterioscler Thromb Vasc Biol. 2003 Jun 1;23(6):931-9. doi: 10.1161/01.ATV.0000070100.47907.26. Epub 2003 Apr 3.
5
A protease activated receptor-2 (PAR-2) activating peptide, tc-LIGRLO-NH2, induces protease release from mast cells: role in TNF degradation.
BMC Pharmacol. 2004 Jul 20;4:12. doi: 10.1186/1471-2210-4-12.
6
Paracoccidioides brasiliensis induces cytokine secretion in epithelial cells in a protease-activated receptor-dependent (PAR) manner.
Med Microbiol Immunol. 2017 Apr;206(2):149-156. doi: 10.1007/s00430-016-0490-x. Epub 2016 Dec 19.
7
Colonic luminal proteases activate colonocyte proteinase-activated receptor-2 and regulate paracellular permeability in mice.
Neurogastroenterol Motil. 2007 Jan;19(1):57-65. doi: 10.1111/j.1365-2982.2006.00851.x.
8
Protease-activated receptors: how proteases signal to cells to cause inflammation and pain.
Semin Thromb Hemost. 2006 Apr;32 Suppl 1:39-48. doi: 10.1055/s-2006-939553.
9
Protease activated receptor 2: a new target for IBS treatment.
Eur Rev Med Pharmacol Sci. 2008 Aug;12 Suppl 1:95-102.
10
Proteinase-activated receptor pharmacology: trickier and trickier.
Br J Pharmacol. 2004 Oct;143(4):441. doi: 10.1038/sj.bjp.0705949. Epub 2004 Sep 20.
引用本文的文献
1
Recent Advances in Anti-Atherosclerosis and Potential Therapeutic Targets for Nanomaterial-Derived Drug Formulations.
Adv Sci (Weinh). 2023 Oct;10(29):e2302918. doi: 10.1002/advs.202302918. Epub 2023 Sep 12.
2
Pleiotropic Effects of the Protease-Activated Receptor 1 (PAR1) Inhibitor, Vorapaxar, on Atherosclerosis and Vascular Inflammation.
Cells. 2021 Dec 13;10(12):3517. doi: 10.3390/cells10123517.
3
Targeting Platelet in Atherosclerosis Plaque Formation: Current Knowledge and Future Perspectives.
Int J Mol Sci. 2020 Dec 21;21(24):9760. doi: 10.3390/ijms21249760.
4
Antithrombotic Therapy: Prevention and Treatment of Atherosclerosis and Atherothrombosis.
Handb Exp Pharmacol. 2022;270:103-130. doi: 10.1007/164_2020_357.
5
Ticagrelor Inhibits Toll-Like and Protease-Activated Receptor Mediated Platelet Activation in Acute Coronary Syndromes.
Cardiovasc Drugs Ther. 2020 Feb;34(1):53-63. doi: 10.1007/s10557-019-06932-7.
6
Protease Activity in Vascular Disease.
Arterioscler Thromb Vasc Biol. 2019 Oct;39(10):e210-e218. doi: 10.1161/ATVBAHA.119.312413. Epub 2019 Sep 25.
7
Roles of Coagulation Proteases and PARs (Protease-Activated Receptors) in Mouse Models of Inflammatory Diseases.
Arterioscler Thromb Vasc Biol. 2019 Jan;39(1):13-24. doi: 10.1161/ATVBAHA.118.311655.
本文引用的文献
1
Noncanonical Matrix Metalloprotease 1-Protease-Activated Receptor 1 Signaling Drives Progression of Atherosclerosis.
Arterioscler Thromb Vasc Biol. 2018 Jun;38(6):1368-1380. doi: 10.1161/ATVBAHA.118.310967. Epub 2018 Apr 5.
2
PAR2 (Protease-Activated Receptor 2) Deficiency Attenuates Atherosclerosis in Mice.
Arterioscler Thromb Vasc Biol. 2018 Jun;38(6):1271-1282. doi: 10.1161/ATVBAHA.117.310082. Epub 2018 Mar 29.
3
PAR1 biased signaling is required for activated protein C in vivo benefits in sepsis and stroke.
Blood. 2018 Mar 15;131(11):1163-1171. doi: 10.1182/blood-2017-10-810895. Epub 2018 Jan 17.
4
Protease-Activated Receptor-2 Deficiency Attenuates Atherosclerotic Lesion Progression and Instability in Apolipoprotein E-Deficient Mice.
Front Pharmacol. 2017 Sep 14;8:647. doi: 10.3389/fphar.2017.00647. eCollection 2017.
5
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease.
N Engl J Med. 2017 Oct 5;377(14):1319-1330. doi: 10.1056/NEJMoa1709118. Epub 2017 Aug 27.
6
Platelet-localized FXI promotes a vascular coagulation-inflammatory circuit in arterial hypertension.
Sci Transl Med. 2017 Feb 1;9(375). doi: 10.1126/scitranslmed.aah4923.
7
Factor XI Deficiency Protects Against Atherogenesis in Apolipoprotein E/Factor XI Double Knockout Mice.
Arterioscler Thromb Vasc Biol. 2016 Mar;36(3):475-81. doi: 10.1161/ATVBAHA.115.306954. Epub 2016 Jan 21.
8
Rivaroxaban, a novel oral anticoagulant, attenuates atherosclerotic plaque progression and destabilization in ApoE-deficient mice.
Atherosclerosis. 2015 Oct;242(2):639-46. doi: 10.1016/j.atherosclerosis.2015.03.023. Epub 2015 Mar 19.
9
EPCR-dependent PAR2 activation by the blood coagulation initiation complex regulates LPS-triggered interferon responses in mice.
Blood. 2015 Apr 30;125(18):2845-54. doi: 10.1182/blood-2014-11-610717. Epub 2015 Mar 2.
10
Kallikrein 6 signals through PAR1 and PAR2 to promote neuron injury and exacerbate glutamate neurotoxicity.
J Neurochem. 2013 Oct;127(2):283-98. doi: 10.1111/jnc.12293. Epub 2013 May 27.
Zotero 插件